DOWNLOAD REQUEST - FCF LIFE SCIENCES RESEARCH SERIES
FCF Life Sciences engages in research on recent financing trends in the Life Sciences sector, i.e. biotechnology, pharma and med-tech. FCF primarily focuses on the latest activities in the equity capital markets: Venture Capital, Initial Public Offerings (IPO) and Equity Valuations.
The findings are regularly published in:
NEWS & PRESS
FCF Biotech Venture Capital Monitor – USA 11/2021 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Biotech Venture Capital Monitor – USA 11/2021”. The Monitor is a monthly published overview of venture capital trends in the US-Biotech sector. As
In-Licensing by Chinese Biotech Companies on the rise
An increasing number of drugs of European origin have been in-licensed to Chinese biotechnology companies. Over the last five years, a steady increase in the number of yearly in-licensed assets from Europe can be observed.
Venture Capital Sentiment Tracker – November 2021
November 2021: Biotechnology Medical Technology Health Technology Funding Volume (€m) 0 Trend Funding Volume (€m) 0 Trend Funding Volume (€m) 0 Trend Biotechnology Funding Volume (€m) 0 Trend Medical Technology Funding Volume (€m) 0 Trend
FCF Life Sciences Venture Capital Monitor – Europe 11/2021 published
FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Life Sciences Venture Capital Monitor – Europe 11/2021”. The Monitor is a monthly published overview of venture capital trends in the European Life
VC market for cannabis gains momentum
Investment into US and European cannabis companies have been continuously increasing over the past years. Whereas 72 venture capital transactions were conducted in 2016, the number of transactions in 2021 (YTD) have increased by almost